A Phase 1 interventional study of sitagliptin phosphate and sitagliptin phosphate in Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 98th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 23 in phase 1, and was the 34th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 104th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 55 in phase 1, and was the 33rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitagliptin 100 mg
Drug: sitagliptin phosphate
sitagliptin 200 mg
Drug: sitagliptin phosphate
Placebo
Drug: Comparator: Placebo
sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
Also known as: MK0431
sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
Also known as: MK0431
sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
24-hour Weighted Mean Glucose (WMG)
The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC(0-24 hr)) divided by 24 using linear trapezoidal method.
Time frame: Day 7 of Treatment Period I. Due to a carry-over effect that was observed between treatment periods, efficacy results are presented from Treatment Period I only.
First Patient In: 17-Oct-2007; Last Patient Last Visit: 01-Jul-2008; Seventeen medical clinics worldwide (8 in the United States, 8 in Europe and 1 in Mexico).
| Milestone | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo |
|---|---|---|---|---|---|---|
| Started | 17 | 16 | 20 | 18 | 14 | 18 |
| Completed | 17 | 15 | 17 | 17 | 14 | 16 |
| Not completed | 0 | 1 | 3 | 1 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol specified criteria | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 2 | 1 | 0 | 0 |
| Milestone | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo |
|---|---|---|---|---|---|---|
| Started | 17 | 15 | 17 | 17 | 14 | 16 |
| Completed | 13 | 13 | 13 | 13 | 13 | 11 |
| Not completed | 4 | 2 | 4 | 4 | 1 | 5 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 3 | 2 | 3 | 3 | 1 | 4 |
| Milestone | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo |
|---|---|---|---|---|---|---|
| Started | 13 | 13 | 13 | 13 | 13 | 11 |
| Completed | 11 | 12 | 12 | 12 | 11 | 8 |
| Not completed | 2 | 1 | 1 | 1 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 2 | 1 | 1 | 1 | 1 | 2 |
| Milestone | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo |
|---|---|---|---|---|---|---|
| Started | 11 | 12 | 12 | 12 | 11 | 8 |
| Completed | 7 | 8 | 10 | 8 | 7 | 5 |
| Not completed | 4 | 4 | 2 | 4 | 4 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 4 | 2 | 4 | 3 | 3 |
| Milestone | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo |
|---|---|---|---|---|---|---|
| Started | 7 | 8 | 10 | 8 | 7 | 5 |
| Completed | 7 | 8 | 9 | 8 | 6 | 4 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol specified criteria | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 0 | 0 |
The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC(0-24 hr)) divided by 24 using linear trapezoidal method.
| mg/dL | Sitagliptin 200mg | Sitagliptin 100mg | Placebo |
|---|---|---|---|
| 24-hour Weighted Mean Glucose (WMG) | 169.1 (153.8 to 184.4) | 159.0 (143.1 to 174.9) | 200.9 (186.1 to 215.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 200 mg | — | 0/78 (0%) | 4/78 (5.1%) |
| Sitagliptin 100 mg | — | 0/72 (0%) | 2/72 (2.8%) |
| Placebo | — | 0/74 (0%) | 4/74 (5.4%) |
| Event | Sitagliptin 200 mg | Sitagliptin 100 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 4/78 | 2/72 | 4/74 |
| Age, Continuous(years) | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.5 ± 8.4 | 56.6 ± 5.8 | 55.7 ± 7.2 | 55.3 ± 8.3 | 50.0 ± 10.0 | 48.6 ± 9.6 | 53.5 ± 8.6 |
| Sex: Female, Male(Participants) | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 5 | 7 | 4 | 4 | 3 | 28 |
| Male | 12 | 11 | 13 | 14 | 10 | 15 | 75 |
| Race/Ethnicity, Customized(participants) | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo | Total |
|---|---|---|---|---|---|---|---|
| White | 12 | 14 | 15 | 15 | 11 | 12 | 79 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other | 5 | 2 | 5 | 3 | 3 | 5 | 23 |
| Fasting Plasma Glucose(mg/dL) | Placebo / 100 mg / 200 mg | 100 mg / 200 mg / Placebo | 200 mg / Placebo / 100 mg | Placebo / 200 mg / 100 mg | 100 mg / Placebo / 200 mg | 200 mg / 100 mg / Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 179.3 ± 32.1 | 167.0 ± 41.1 | 184.0 ± 42.1 | 173.2 ± 43.2 | 158.5 ± 17.3 | 166.0 ± 36.5 | 172.0 ± 36.9 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Aug 2007 to primary completion in Jun 2008, 9 months.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.
Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin